| dc.description.abstract | M2 proton channel of influenza A virus is the target protein of anti-flu drugs
Amantadine and Rimantadine. However, these two powerful adamantane-based
drugs lost their bioactivity because of mutations of virus in recent twenty years.
There is a great urgent need to discover new promising M2 channel inhibitors based
on computer-aided drug design methods. The structure of the M2 channel proteins
of H3N2 (PDB code 2RLF) and 2009-H1N1 viruses (Genbank accession number
GQ385383) may help researchers to solve the drug-resistant problem of these two
adamantane-based drugs and develop more powerful new drugs against influenza A
virus. Searching for new M2 channel inhibitors in this study was based on a
combination of different computational methodologies, including attaching new
functional groups to Amantadine scaffold, virtual screening with docking and
pharmacophore modeling. Virtual screening was performed to calculate the free
binding energies between receptor M2 channel proteins and 200 new designed
ligands with the pharmacophore techniques to analyze the important M2 protein-
inhibitor interactions and give the best common features of top binding compounds
with M2 channel proteins. Finally, two most potential compounds were proposed as
novel leads to inhibit M2 channel proteins in both H3N2 and 2009-H1N1 influenza A
virus.
Keywords: M2 channel inhibitors, adamantane-based drugs, Amantadine scaffold, virtual screening, pharmacophore analysis. | en_US |
